Maev I V, Kucheravy Yu A, Tsukanov V V, Eremnia E Yu, Andreev D N, Abdulhakov S R, Akhmedov V A, Batskov S S, Vasyutin A V, V'yuchnova E S, Ivanchenko D N, Luzina E V, Krapivnaya O V, Onuchina E V, Osipenko M F, Simanenkov V I, Tonkih Yu L, Khomeriki N M, Shklyaev A E, Akimov A V, Sokolov K A
A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
Federal Research Centre "Krasnoyarsk Science Centre" of the Siberian Branch of Russian Academy of Science"(FRC KSC SB RAS), Scientific Research Institute of medical problems of the North (SRI MPN), Krasnoyarsk, Russia.
Ter Arkh. 2018 Aug 27;90(8):40-47. doi: 10.26442/terarkh201890840-47.
To assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment.
218 patients were included in 16 clinical centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not requiring surgical treatment and received mebeverine (Duspatalin®) 200 mg BID. The observational assessment period lasted from the moment of their inclusion into the study up to 6 weeks post inlusion. The therapy results were evaluated using visual analog scales (GPA and 11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort and other post-cholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment. Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life.
All 218 patients completed the 2-week mebeverine treatment course, 101 of them finished the 6-week course ("prolonged population"). Significant positive changes in the relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency and consistency. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of patients was observed comparable to cholecystectomy itself, speficially related to the quality of life subscore 'symptoms'.
The results of our study demonstrate that mebeverine (Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with post-cholecystectomy GI-spasm disorders, like abdominal pain, symptoms of dyspepsia and stooldisorders. A more marked change in values was observed during prolonged (up to 6 weeks) therapy.
